Nurix Therapeutics, Inc.
Net SellingNRIX·US·🇺🇸 US
0%buys·100%sells
964 transactions$0Total buys·0 buys
$10.4MTotal sells·155 sells
3939 insiders
Last: Apr 2, 2026
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Apr 2, 26 | Ring Christine | Sell | $124K | |
| Dec 18, 25 | Ring Christine | Exercise | - | |
| Dec 18, 25 | Ring Christine | Exercise | $7K | |
| Dec 18, 25 | Ring Christine | Sell | $4K | |
| Dec 18, 25 | Ring Christine | Sell | $64K | |
| Nov 24, 25 | Ring Christine | Exercise | - | |
| Nov 24, 25 | Ring Christine | Exercise | $70K | |
| Nov 24, 25 | Ring Christine | Sell | $642K | |
| Nov 6, 25 | DANSEY ROGER D | Grant | - | |
| Nov 3, 25 | van Houte Hans | Sell | $79K |
van Houte Hans (CFO) recently executed a sell of $79K in Nurix Therapeutics, Inc. shares on November 3, 2025. Overall insider sentiment is bearish (100% sales).
Nurix Therapeutics, Inc. (NRIX) has recorded 964 insider operations, including 0 open-market purchases ($0), 155 sales ($10.4M) and 809 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bearish (100% sales).
Insider activity at Nurix Therapeutics, Inc. is sustained, with operations recorded in 9 of the last 12 months — a sign of regular regulatory filings.
Among the most active insiders are SANDS ARTHUR T (CEO), van Houte Hans (CFO) & Ring Christine (C SUITE), with respectively 48, 124, 206 transactions.
Across all 964 recorded transactions, the breakdown by type is: exercise (534, 55%), other (192, 20%), sells (155, 16%), grant (82, 9%), gift (1, 0%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Nurix Therapeutics, Inc. has recorded 964 insider operations in total, including 0 open-market purchases ($0), 155 sales ($10.4M) and 809 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on April 2, 2026.
Insiders at Nurix Therapeutics, Inc. are currently net sellers, with 0% purchases and 100% sales across all reported transactions. Total buy volume is $0 versus $10.4M in sales, indicating a bearish insider sentiment.
InsiderLens tracks 39 insiders at Nurix Therapeutics, Inc. (NRIX). SANDS ARTHUR T (CEO, 48 tx), van Houte Hans (CFO, 124 tx), Ring Christine (C SUITE, 206 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for NRIX is bearish, based on a 0% buy ratio across 155 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Nurix Therapeutics, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.